Abstract
Amyloid β-protein (Aβ) is one of the most studied peptides in human neurodegenerative disorders. Although much has been learned about the biochemistry of this peptide, fundamental questions such as when and how the Aβ becomes pathologic remain unanswered. In this article we review the recent findings on the biology and pathology of Aβ and the role protein kinase C (PKC) plays in these processes. The potential neuroprotective role of PKC and the possible therapeutic effects of PKC activators in Alzheimer's disease (AD) will be discussed. Briefly, comments will be also addressed on the role of PKC in cell death and neurogenesis in AD.
| Original language | English |
|---|---|
| Pages (from-to) | 1-5 |
| Number of pages | 5 |
| Journal | Journal of Pharmacological Sciences |
| Volume | 97 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 01-2005 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Pharmacology
Fingerprint
Dive into the research topics of 'Amyloid pathology and protein kinase C (PKC): Possible therapeutics effects of PKC activators'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver